(Q42992806)

12 November 2017

Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma (English)

1 reference

12 November 2017

1 reference

1 reference

Kosei Matsue

1

1 reference

12 November 2017

Shun-ichi Kimura

2

1 reference

12 November 2017

Yoko Takanashi

3

1 reference

12 November 2017

Kan-ichi Iwama

4

1 reference

12 November 2017

Hideaki Fujiwara

5

1 reference

12 November 2017

Masayuki Yamakura

6

1 reference

12 November 2017

Masami Takeuchi

7

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

12 November 2017

1 reference

12 November 2017

116

1 reference

12 November 2017

20

1 reference

12 November 2017

4769-4776

1 reference

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

12 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

How I treat patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Hepatitis B virus DNA contains a glucocorticoid-responsive element

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

From a medical mistake to a clinical warning: the case of HBV mutant virus reactivation in haematological patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25253

7 January 2021

Identifiers

DOI

10.1002/CNCR.25253

1 reference

12 November 2017

1 reference